吉林大学学报(医学版) ›› 2021, Vol. 47 ›› Issue (2): 528-536.doi: 10.13481/j.1671-587X.20210236
• 综述 • 上一篇
收稿日期:
2020-07-11
出版日期:
2021-03-28
发布日期:
2021-03-25
通讯作者:
金艳花
E-mail:jinyanhua@ybu.edu.cn
作者简介:
胡婷婷(1994-),女,吉林省松原市人,在读硕士研究生,主要从事生物化学与分子生物学和表观遗传学方面的研究。
基金资助:
Received:
2020-07-11
Online:
2021-03-28
Published:
2021-03-25
摘要:
在肿瘤的表观遗传学中,组蛋白乙酰化和(或)去乙酰化是其调控基因表达的主要驱动力。目前,组蛋白去乙酰化酶(HDACs)参与癌细胞形成与发展的具体机制仍有待进一步研究。组蛋白去乙酰化酶8(HDAC8)属于Ⅰ类HDAC家族成员,是重要的表观遗传因子之一,其通过催化组蛋白去乙酰化导致局部染色质结构呈压缩和(或)关闭状态而抑制基因转录,还可催化去乙酰化组蛋白之外的蛋白,从而起到对生物大分子的调节作用。HDAC8参与基因转录调控、肿瘤发生发展、细胞增殖、细胞分化和凋亡等重要过程。现就近几年有关HDAC8的结构以及其在胃癌、结肠癌、肺癌、乳腺癌和神经母细胞瘤等多种肿瘤发展中的作用作一综述,旨在更深入了解其功能,并为肿瘤治疗提供新思路。
中图分类号:
胡婷婷,朴光宇,金艳花. 组蛋白去乙酰化酶8在肿瘤发展中作用的研究进展[J]. 吉林大学学报(医学版), 2021, 47(2): 528-536.
1 | GALLINARI P, DI MARCO S, JONES P, et al. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics [J]. Cell Res, 2007, 17(3):195-211. |
2 | HABERLAND M, MONTGOMERY R L, OLSON E N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy [J]. Nat Rev Genet , 2009, 10(1):32-42. |
3 | CHAKRABARTI A, OEHME I, WITT O, et al. HDAC8: a multifaceted target for therapeutic interventions [J]. Trends Pharmacol Sci, 2015, 36(7):481-492. |
4 | AMIN S A, ADHIKARI N, JHA T. Structure-activity relationships of hydroxamate-based histone deacetylase-8 inhibitors: reality behind anticancer drug discovery [J]. Future Med Chem,2017, 9(18):2211-2237. |
5 | SOMOZA J R, SKENE R J, KATZ B A, et al. Structural snapshots of human HDAC8 provide insights into the class Ⅰ histone deacetylases [J]. Structure, 2004 , 12(7):1325-1334. |
6 | DOWLING D P, GANTT S L, GATTIS S G, et al. Structural studies of human histone deacetylase 8 and its site-specific variants complexed with substrate and inhibitors [J]. Biochemistry,2008,47(51):13554-13563. |
7 | VANNINI A, VOLPARI C, GALLINARI P, et al. Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8-substrate complex [J]. EMBO Rep,2007,8(9):879-884. |
8 | PORTER N J, CHRISTIANSON N H, DECROOS C, et al. Structural and functional influence of the glycine-rich loop G302 GGGY on the catalytic tyrosine of histone deacetylase 8[J].Biochemistry,2016,55(48):6718-6729. |
9 | ESTIU G, WEST N, MAZITSCHEK R, et al. On the inhibition of histone deacetylase 8 [J]. Bioorg Med Chem,2010,18(11):4103-4110. |
10 | GANTT S M, DECROOS C, LEE M S, et al. General base-general acid catalysis in human histone deacetylase 8 [J].Biochemistry,2016,55(5):820-832. |
11 | TABACKMAN A A,FRANKSON R,MARSAN E S, et al.Structure of ‘linkerless’ hydroxamic acid inhibitor-HDAC8 complex confirms the formation of an isoform-specific subpocket [J]. J Struct Biol,2016,195(3):373-378. |
12 | MAREK M, SHAIK T B, HEIMBURG T, et al. Characterization of histone deacetylase 8 (HDAC8) selective inhibition reveals specific active site structural and functional determinants [J]. Med Chem, 2018,61(22):10000-10016. |
13 | LOMBARDI P M,COLE K E,DOWLING D P,et al.Structure, mechanism, and inhibition of histone deacetylases and related metalloenzymes [J]. Curr Opin Struct Biol, 2011, 21(6):735-743. |
14 | LI Z M, ZHU W G. Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications [J]. Int J Biol Sci, 2014, 10(7):757-770. |
15 | LEE H, REZAI-ZADEH N, SETO E. Negative regulation of histone deacetylase 8 activity by cyclic AMP-dependent protein kinase A [J]. Mol Cell Biol,2004,24(2):765-773. |
16 | NAKAGAWA M, ODA Y, EGUCHI T, et al. Expression profile of class I histonedeacetylases in human cancer tissues [J]. Oncol Rep, 2007,18(4):769-774. |
17 | SONG S Y, WANG Y, XU P, et al. The inhibition of histone deacetylase 8 suppresses proliferation and inhibits apoptosis in gastric adenocarcinoma [J]. Int J Oncol, 2015,47(5):1819-1828. |
18 | WANG Y, XU P, YAO J, et al. MicroRNA-216b is Down-regulated in human gastric adenocarcinoma and inhibits proliferation and cell cycle progression by targeting oncogene HDAC8 [J]. Targ Oncol, 2016, 11(6):839. |
19 | SIEGEL R L,MILLER K D,JEMAL A.Cancer statistics,2019 [J]. CA Cancer J Clin, 2019, 69(1):7-34. |
20 | SAIJO H, HIROHASHI Y, TORIGOE T, et al. Plasticity of lung cancer stem-like cells is regulated by the transcription factor HOXA5 that is induced by oxidative stress[J]. Oncotarget,2016,7(31):50043-50056. |
21 | LI Y, LIANG R, SUN M, et al. AMPK-dependent phosphorylation of HDAC8 triggers PGM1 expression to promote lung cancer cell survival under glucose starvation [J]. Cancer Lett , 2020 , 478:82-92. |
22 | WU J, DU C L, LV Z, et al.The up-regulation of histone deacetylase 8 promotes proliferation and inhibits apoptosis in hepatocellular carcinoma [J]. Dig Dis Sci, 2013, 58(12):3545-3553. |
23 | ZHU Y J, XU Q, SHAO M Y, et al. Decreased expression of HDAC8 indicates poor prognosis in patients with intrahepatic cholangiocarcinoma [J]. Hepatobiliary Pancreat Dis Int,2019 , 18(5):464-470. |
24 | TIAN Y, WONG V W, WONG G L, et al. Histone Deacetylase HDAC8 promotes insulin resistance and β-catenin ativation in NAFLD-associated hepatocellular carcinoma[J].Cancer Res, 2015, 75(22):4803-4816. |
25 | BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424. |
26 | GOURD E. Low uptake of tamoxifen to prevent breast cancer [J]. Lancet Oncol,2018,19(6):E290. |
27 | KANG J, SOHN J S, LEE H Y, et al. Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer [J]. Oncol Rep, 2011,25(6):167. |
28 | MENBARI M N, RAHIMI K, AHMADI A, et al. Abdi M. miR-483-3p suppresses the proliferation and progression of human triple negative breast cancer cells by targeting the HDAC8>oncogene [J]. J Cell Physiol, 2020,235(3):2631-2642. |
29 | CHIU C F, CHIN H K, HUANG W J, et al. Induction of apoptosis and autophagy in breast cancer cells by a novel HDAC8 inhibitor [J]. Biomolecules,2019,9(12):824. |
30 | JANA S, SENGUPTA S, BISWAS S, et al. miR-216b suppresses breast cancer growth and metastasis by targeting SDCBP [J]. Biochem Biophys Res Commun, 2017,482(1):126-133. |
31 | MENBARI M N, RAHIMI K, AHMADI A, et al. MiR-216b-5p inhibits cell proliferation in human breast cancer by down-regulating HDAC8 expression [J]. Life Sci,2019,237:116945. |
32 | OEHME I, DEUBZER H E, WEGENER D, et al. Histone deacetylase 8 in neuroblastoma tumorigenesis [J]. Clin Cancer Res, 2009, 15(1):91-99. |
33 | OEHME I, DEUBZER H E, LODRINI M, et al. Targeting of HDAC8 and investigational inhibitors in neuroblastoma [J]. Expert Opin Investig Drugs,2009, 18(11):1605-1617. |
34 | RETTIG I, KOENEKE E, TRIPPEL F, et al. Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation [J]. Cell Death Dis, 2015(2):e1657. |
35 | SHEN J, NAJAFI S, STÄBLE S, et al. A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment [J]. Cell Death Differ,2018,25(12):2053‐2070. |
36 | PRASHAD N. miR-665 targets c-MYC and HDAC8 to inhibit murine neuroblastoma cell growth [J]. Oncotarget,2018,9(69):33186-33201. |
37 | KOLBINGER F R, KOENEKE E, RIDINGER J, et al. The HDAC6/8/10 inhibitor TH34 induces DNA damage-mediated cell death in human high-grade neuroblastoma cell lines [J]. Arch Toxicol,2018,92(8):2649-2664. |
38 | BISWAS S, REDDY N D, JAYASHREE B S, et al. Evaluation of novel 3-hydroxyflavone analogues as HDAC inhibitors against colorectal cancer [J]. Adv Pharmacol Sci, 2018,2018:4751806. |
39 | YAN W, LIU S, XU E, et al. Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8 [J]. Oncogene,2013, 32(5):599-609. |
40 | KANG Y, NIAN H, RAJENDRAN P, et al. HDAC8 and STAT3 repress BMF gene activity in colon cancer cells [J]. Cell Death Dis,2014,5:e1476. |
41 | ZHANG B J, LIU B, CHEN D, et al. Histone Deacetylase inhibitors sensitize TRAIL-induced apoptosis in colon cancer cells[J].Cancers,2019,11(5):645. |
42 | DOHNER H, ESTEY E H, AMADORI S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net[J]. Blood,2010,115(3):453-474. |
43 | LONG J, JIA M Y, FANG W Y, et al. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia [J]. Blood,2020,135(17):1472-1483. |
44 | GHAZY E, ZEYEN P, HERP D, et al. Design, synthesis, and biological evaluation of dual targeting inhibitors of histone deacetylase 6/8 and bromodomain BRPF1 [J]. Eur J Med Chem,2020,200:112338. |
45 | TASHI T, SWIERCZEK S, PRCHAL J T. Familial MPN predisposition [J]. Curr Hematol Malig Rep, 2017,12(5):442-447. |
46 | GAO S M, CHEN C Q, WANG L Y, et al. Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms[J]. Exp Hematol,2013, 41(3):261-270.e4. |
47 | RAMOS T L, SÁNCHEZ-ABARCA L I, REDONDO A, et al. HDAC8 overexpression in mesenchymal stromal cells from JAK2+ myeloproliferative neoplasms: a new therapeutic target?[J].Oncotarget,2017,8(17):28187-28202. |
48 | SIMOBEN C V, ROBAA D, CHAKRABARTI A, et al. A novel class of schistosoma mansoni histone deacetylase 8 (HDAC8) inhibitors identified by structure-based virtual screening and in vitro testing [J]. Molecules,2018,23(3):566. |
49 | YAMAUCHI Y, BOUKARI H, BANERJEE I, et al. Histone deacetylase 8 is required for centrosome cohesion and influenza A virus entry [J]. PLoS Pathog, 2011,7(10):e1002316. |
50 | BERTRAND P. Inside HDAC with HDAC inhibitors [J]. Eur J Med Chem, 2010,45(6):2095-2116. |
51 | 李 群,王 剑,王秀敏.德朗热综合征的分子机制及诊治研究进展[J]. 医学综述, 2019,25(8):1614-1619. |
52 | DEARDORFF M A, BANDO M, NAKATO R, et al. HDAC8 mutations in Cornelia de Lange syndrome affect the cohesin acetylation cycle[J].Nature,2012,489(7415):313-317. |
53 | AMIN S A, ADHIKARI N, JHA T. Is dual inhibition of metalloenzymes HDAC-8 and MMP-2 a potential pharmacological target to combat hematological malignancies? [J]. Pharmacol Res,2017,122:8-19. |
54 | AMIN S A, ADHIKARI N, JHA T. Diverse classes of HDAC8 inhibitors: in search of molecular fingerprints that regulate activity [J].Future Med Chem,2018,10(13):1589-1602. |
55 | BALASUBRAMANIAN S, VERNER E, BUGGY J J. Isoform-specific histone deacetylase inhibitors: the next step? [J]. Cancer Lett,2009, 280(2):211-221 |
56 | AMIN S A, ADHIKARI N, JHA T. Structure-activity relationships of hydroxamate-based histone deacetylase-8 inhibitors: reality behind anticancer drug discovery [J]. Future Med Chem, 2017, 9(18):2211-2237. |
57 | SODJI Q H, KORNACKI J R, MCDONALD J F,et al.Design and structure activity relationship of tumor-homing histone deacetylase inhibitors conjugated to folic and pteroic acids [J].Eur J Med Chem,2015,96:340-359. |
58 | KALININ D V, JANA S K, PFAFENROT M, et al. Front cover:structure-based design, synthesis, and biological evaluation of triazole-based smHDAC8 Inhibitors [J]. Chem Med Chem,2020,15(7):559. |
59 | WOLFF B, JÄNSCH N, SUGIARTO W O, et al. Synthesis and structure activity relationship of 1,3-benzo-thiazine-2-thiones as selective HDAC8 inhibitors [J]. Eur J Med Chem, 2019, 184:111756. |
60 | WHITEHEAD L,DOBLER M R,RADETICH B,et al.Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors [J]. Bioorg Med Chem, 2011, 19(15):4626-4634. |
61 | INGHAM O J, PARANAL R M, SMITH W B, et al. Development of a potent and selective HDAC8 inhibitor [J]. ACS Med Chem Lett, 2016,7(10):929-932. |
62 | WÜNSCH M, SENGER J, SCHULTHEISZ P, et al. Structure-activity relationship of propargylamine-based HDAC inhibitors [J]. Chem Med Chem,2017,12(24): 2044-2053. |
63 | ZHAO C, ZANG J, DING Q, et al. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors [J]. Eur J Med Chem,2018, 150:282-291. |
64 | LAMAA D, LIN H P, ZIG L, et al. Design and Synthesis of tubulin and histone deacetylase inhibitor based on iso-combretastatin A-4 [J].Med Chem,2018,61(15):6574-6591. |
65 | ADHIKARI N, AMIN S A, JHA T. Selective and nonselective HDAC8 inhibitors: a therapeutic patent review [J]. Pharm Pat Anal,2018,7(6):259-276. |
*延边大学医学院2017级麻醉学专业 |
[1] | 王琴,林春霖,程志彬,何若凡,林鹏航,陈辉,叶建新,朱广伟. 肿瘤坏死因子受体相关因子6泛素化位点突变载体的构建及其功能位泛素化位点的鉴定[J]. 吉林大学学报(医学版), 2021, 47(3): 551-558. |
[2] | 母润红,刘馨竹,林睿,李雨澎,王璐瑶,王春雨,郭笑. PRDX6过表达对肝癌细胞增殖、侵袭和迁移的影响及其分子机制[J]. 吉林大学学报(医学版), 2021, 47(3): 559-565. |
[3] | 任英俊,张慧,周颖. 敲低着丝粒蛋白U对顺铂耐药卵巢癌细胞自我更新、顺铂耐药和Wnt/β-catenin信号活性的抑制作用[J]. 吉林大学学报(医学版), 2021, 47(3): 608-614. |
[4] | 马博,李建刚,王俊,候军丽,李亮. miR-106b靶向调控TGF-β/Smad通路对结肠癌细胞侵袭和迁移的促进作用[J]. 吉林大学学报(医学版), 2021, 47(3): 630-636. |
[5] | 穆春青,周磊,赵楠,王红,李智. 二甲双胍通过PI3K/AKT/GSK3β信号通路对肺癌A549细胞增殖的影响[J]. 吉林大学学报(医学版), 2021, 47(3): 637-643. |
[6] | 巩培,刘竟然,赵世敏,王玉珍,谢基明. MCM10沉默对乳腺癌MDA-MB-231细胞的增殖抑制作用及其机制[J]. 吉林大学学报(医学版), 2021, 47(3): 652-659. |
[7] | 李晓辉,瞿紫微,卢昕,孟庆彬,陈华涛,任骏,谭成沛. 骨髓间充质干细胞来源性外泌体携带miR-196b-5p对结肠癌细胞生物学特性的调控作用[J]. 吉林大学学报(医学版), 2021, 47(3): 660-668. |
[8] | 冯曜宇,张承磊,侯丽娟,王益夫,吴秀玲,马云海. 敲降miR-222-3p靶向PTEN对甲状腺癌131I放疗抵抗的影响及其机制[J]. 吉林大学学报(医学版), 2021, 47(3): 677-686. |
[9] | 杨颖,赵伟,吕丹. C19ORF12对胃癌MKN45细胞增殖和化疗药敏感性的影响及其机制[J]. 吉林大学学报(医学版), 2021, 47(3): 687-693. |
[10] | 王聪,郭秀,迟昊,张捷,许溟宇,董春玲. 简化版Wells评分、修订版Geneva评分和D-二聚体水平在恶性肿瘤并发肺血栓栓塞症诊断中的应用价值[J]. 吉林大学学报(医学版), 2021, 47(3): 707-713. |
[11] | 卢瑞云,谷敬锋,张建,张新,徐菲. miR-30a-5p靶向调控TRIM31表达对结直肠癌细胞5-氟尿嘧啶耐药的逆转作用及其机制[J]. 吉林大学学报(医学版), 2021, 47(3): 714-723. |
[12] | 王青,解思琦,郑凯,唐一吟,李红万,张恒瑀,谭明建,彭蕾,刘德权,唐诗聪. 接受不同化疗方案乳腺癌患者血清B族维生素水平检测及其临床意义[J]. 吉林大学学报(医学版), 2021, 47(3): 724-730. |
[13] | 苏丹,刘屹,崔慢慢,杨年,黄宇,何文静. 基于miniPDX动物模型筛选化疗方案治疗卵巢癌的临床效果评价[J]. 吉林大学学报(医学版), 2021, 47(3): 731-739. |
[14] | 陈东,李支尧,陈海涛,钏志睿,张映贤,金鑫,唐诗聪,罗晓茂. 直肠腔内三维超声和MRI检测对中下段直肠癌患者术前T分期和环周切缘的诊断价值[J]. 吉林大学学报(医学版), 2021, 47(3): 753-760. |
[15] | 吴越,杨帅,周晶晶,李真胜男,孟宪瑛,臧晓军. 甲状腺交界性肿瘤诊断和预后相关分子标志物的研究进展Research progress in diagnosis- and prognosis-related molecular markers of borderline thyroid tumor[J]. 吉林大学学报(医学版), 2021, 47(3): 802-810. |
|